Life Sciences, Healthcare & Pharmaceuticals
Substantial resources are required to finance innovative projects in the life sciences field, frequently requiring young companies to enter strategic agreements with large multinational players. Herzog Fox & Neeman’s Life Sciences, Healthcare & Pharmaceuticals department possesses a unique understanding of all aspects of the business and is the go-to firm for representing businesses in complex collaboration agreements with large global companies.
The department has significant experience working with all relevant parties including: biotech companies, pharmaceutical companies, medical devices and equipment companies, food supplement manufacturers, healthcare providers, medical and research institutions as well as consultants and investors within the industry. The department represents small start-up companies from their inception to exit in either an IPO or M&A transaction, as well as large international pharmaceutical or medical device/equipment companies, advising on all aspects of their commercial, regulatory and transactional activities. Herzog Fox & Neeman's adept corporate skills are coupled with a deep understanding of all the commercial and regulatory aspects of such companies' businesses.
The Life Sciences, Healthcare & Pharmaceuticals department is involved in addressing an extensive variety of agreements such as: founders’ agreements, consultancy, non-disclosure, licence, collaboration, development, joint venture, manufacturing, distribution and M&A agreements, as well as agreements pertaining to obtaining regulatory approvals for manufacturing, marketing and distribution of pharmaceutical and medical devices (e.g., agreements with clinical research organizations, investigators and hospitals) and with various service providers. The department has a unique specialty in representing biotech companies in connection with their collaboration agreements with large pharmaceutical companies.
IP and technology licensing play a key role in Herzog Fox & Neeman’s Life Sciences, Healthcare & Pharmaceuticals department. The department is involved in all areas of intellectual property licensing, with expertise in drafting and negotiating agreements for the research and development, licensing, manufacturing, distribution, sale, branding, marketing, consulting and other forms of commercial exploitation of IP, as well as generating revenue and establishing strategic partnerships. Herzog Fox & Neeman has a unique capability in Israel in advising on Share Purchase Agreements and joint developments/joint ventures with specific IP provisions.
Additionally, the department provides on-going legal services for all major commercial issues specific to the field of pharmaceuticals. This includes handling the legal aspects of the relationship between international pharmaceutical companies and local representatives, in addition to managing the legal issues arising between commercial pharmaceutical companies and healthcare providers. Herzog Fox & Neeman also acts for clients in patent-related litigation and disputes relating to the importation of drugs.
Herzog Fox & Neeman possesses a good working relationship with the Ministry of Health in Israel, including its legal advisor, and various other governmental authorities. The Life Sciences, Healthcare & Pharmaceuticals department regularly represents clients before such regulatory bodies.
Life Sciences, Healthcare & Pharmaceuticals News & Insights
Herzog Fox Neeman invites you to the third Annual Life Sciences Compliance Forum on Corporate Compliance in the fields of
Third Annual Life Sciences Compliance Forum
The “MedTech Tel Aviv” is a tailor-made event for Startups who wish to examine ways to approach the US market.
Med-Tech Tel Aviv
Herzog Fox & Neeman and ACC are pleased to invite you to the Conference of BioMed & Pharma In-House Counsel.
04.07.2019 | Secondary Usage of Health Information | Theoretical and Practical Aspects
The German medical device market is the largest in Europe and the third largest in the world. Some of the
03.06.2019 | Opportunities in the German Medical Device Market | How to Land Smoothly In the EU
WLG Cannabis Group members is hosting a webinar for both member firm lawyers and clients in 2019. Each webinar will focus on
26.02.19 | WLG Cannabis Legalisation Webinar: Israel Update
Herzog Fox & Neeman is proud to invite you to the 2nd Annual Life Sciences Compliance Forum, dedicated to compliance in
2nd Annual Life Sciences Compliance Forum
Herzog Fox & Neeman Partners Yair Geva, Tomer Farkash, Dan Sharot, and Ofer Granot, together with Associate Michal Shirin, represented Israeli biopharmaceutical company Entera Bio
Herzog Fox & Neeman Represents Entera Bio in $270m Amgen Licensing Deal
On the 18th of June, 2018, the Ministry of Health published a circular pertaining to the rules for the commercial
Client Update | Rules for Commercial Engagements of Health Institutions
During the first half of 2018, four amendments to the legislation on cost-control of drug pricing [of preparations] in Israel
Client Update | Changes in Cost-Control Drug Pricing Policy | June 2018
BDI Code has published its 2018 Israel Legal Rankings, where, once again, our firm has been ranked the leading Israeli
BDI Code’s Ranking for 2018: Herzog Fox & Neeman ranked leading law firm in Israel!
Dear clients and friends, In Israel, health information is constantly being processed and recorded on a large scale, and due
Client Update | New Regulation on the Use of Health Data for Research and Commercial Purposes
Dan Shalev
Partner
Artificial Intelligence, Cyber & Data Security, Fintech, Crypto & Blockchain, Internet & E-commerce, Privacy & Data Protection, Social & Real Money Gaming, Technology Regulation, Telecom & Media, eCommerce, Media & Adtech
Ron Ben-Menachem
Partner
Capital Markets & Securities, Corporate, Corporate Finance, Mergers & Acquisitions, Telecom & Media